Healthcare Wiz Mitchell Blutt Bets Big on These 3 Biotech Stocks
Hedge fund manager Mitchell J. Blutt of the $1.5 billion Consonance Capital fund has made some intriguing portfolio shifts in the last quarter, including boosting his position in biopharma firm Catalyst Pharmaceuticals (NASDAQ:
Discover more from USNewsRank
Subscribe to get the latest posts sent to your email.